OncoMatch

OncoMatch/Clinical Trials/NCT05684276

DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors

Is NCT05684276 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Carboplatin and Paclitaxel for nsclc.

Phase 2RecruitingFundación GECPNCT05684276Data as of May 2026

Treatment: Carboplatin · Paclitaxel · NivolumabThe goal of this clinical trial is to test the efficacy of induction treatment of immunotherapy and chemotherapy depending on the resection status for the treatment of non small cell lung cancer patients diagnosed with pancoast tumor. The main objectives it aims to answer are: * Complete resection rate after induction treatment with chemotherapy plus nivolumab * Overall Survival and Progression Free Survival at 24 months The sample size is 40 patients.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Excluded: EGFR activating mutation in the TK domain

activating mutations in the TK domain of EGFR

Excluded: ALK any variety of alterations

any variety of alterations in the ALK gene

Excluded: ROS1 mutation

ROS1 mutations

Disease stage

Required: Stage IIB, IIIA, T3N2 (IIIB) (8th edition of the TNM)

stages IIB, IIIA and T3N2 (IIIB) patients

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: antineoplastic drugs

previous treatment with antineoplastic drugs

Cannot have received: chest radiotherapy

previous treatment with chest radiotherapy

Cannot have received: surgery for lung cancer or for another reason

previous surgery for lung cancer or for another reason

Cannot have received: anti-PD-1 therapy

prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify